Cue Biopharma, Inc.
CUE
$0.84
$0.02182.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 601.66% | -73.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 601.66% | -73.29% | |||
| Cost of Revenue | 3.44% | -21.84% | |||
| Gross Profit | 31.41% | 11.96% | |||
| SG&A Expenses | -27.48% | 257.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.89% | 13.52% | |||
| Operating Income | 29.79% | -27.73% | |||
| Income Before Tax | 30.80% | -29.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.80% | -29.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.80% | -29.08% | |||
| EBIT | 29.79% | -27.73% | |||
| EBITDA | 30.02% | -27.98% | |||
| EPS Basic | 46.15% | -29.09% | |||
| Normalized Basic EPS | 46.22% | -29.16% | |||
| EPS Diluted | 46.15% | -29.09% | |||
| Normalized Diluted EPS | 46.22% | -29.16% | |||
| Average Basic Shares Outstanding | 28.56% | 0.02% | |||
| Average Diluted Shares Outstanding | 28.56% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||